featured
Neoadjuvant Bevacizumab With Docetaxel Followed by Fluorouracil, Epirubicin, and Cyclophosphamide for Women With HER2-Negative Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Neoadjuvant Bevacizumab Added to Docetaxel Followed by Fluorouracil, Epirubicin, and Cyclophosphamide, for Women With HER2-Negative Early Breast Cancer (ARTemis): An Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2015 May 11;[EPub Ahead of Print], HM Earl, L Hiller, JA Dunn, C Blenkinsop, L Grybowicz, AL Vallier, J Abraham, J Thomas, E Provenzano, L Hughes-Davies, I Gounaris, K McAdam, S Chan, R Ahmad, T Hickish, S Houston, D Rea, J Bartlett, C Caldas, DA Cameron, L HaywardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.